Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Darja Schmidt
Observed names:
D Schmidt,
D. Schmidt
Institution:
Bavarian Nordic (Germany)
Observed institutions:
Max Planck Society,
Bavarian Nordic (Germany),
Max Planck Institute of Biochemistry,
Institut für Immunologie,
Ludwig-Maximilians-Universität München
ORCID:
0000-0001-8559-1302
Observed ORCID:
0000-0001-8559-1302
OpenAlex ID:
A5036895915
Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity
2002
·
Darja Schmidt
, Stefan Müller
·
Proceedings of the National Academy of Sciences
·
511
PDF
PIAS/SUMO: new partners in transcriptional regulation
2003
·
D. Schmidt
, S. M�ller
·
Cellular and Molecular Life Sciences
·
313
SUMO: a regulator of gene expression and genome integrity
2004
·
Stefan Müller
, Andreas Ledl
, et al.
·
Oncogene
·
310
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
2019
·
Phillip R. Pittman
, Matthew Hahn
, et al.
·
New England Journal of Medicine
·
256
PDF
Down-Regulation of c-Fos/c-Jun AP-1 Dimer Activity by Sumoylation
2005
·
Guillaume Bossis
, Cécile E. Malnou
, et al.
·
Molecular and Cellular Biology
·
228
Constitutive Crosspresentation of Tissue Antigens by Dendritic Cells Controls CD8+ T Cell Tolerance In Vivo
2008
·
Nancy Luckashenak
, Samira Schroeder
, et al.
·
Immunity
·
152
PDF
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis
2015
·
Richard N Greenberg
, Yadira Hurley
, et al.
·
PLoS ONE
·
113
PDF
Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor
2005
·
Andreas Ledl
, Darja Schmidt
, et al.
·
Oncogene
·
112
Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5
2006
·
Hassan Mziaut
, Mirko Trajkovski
, et al.
·
Nature Cell Biology
·
92
Sumoylation of poly(ADP‐ribose) polymerase 1 inhibits its acetylation and restrains transcriptional coactivator function
2009
·
Simon Messner
, David Schuermann
, et al.
·
The FASEB Journal
·
86
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
2016
·
Richard N. Greenberg
, Christine M. Hay
, et al.
·
PLoS ONE
·
82
PDF
A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS
2020
·
Edgar Turner Overton
, Steven J. Lawrence
, et al.
·
Vaccine
·
69
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
2018
·
Edgar Turner Overton
, Steven J. Lawrence
, et al.
·
PLoS ONE
·
65
PDF
Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine
2020
·
Elke Jordan
, Steven J Lawrence
, et al.
·
The Journal of Infectious Diseases
·
61
Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial
2020
·
Nathaly Samy
, Daniela Reichhardt
, et al.
·
Vaccine
·
59
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
2022
·
Heiko Ilchmann
, Nathaly Samy
, et al.
·
The Journal of Infectious Diseases
·
55
Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine
2023
·
Elke Jordan
, Golam Kabir
, et al.
·
The Journal of Infectious Diseases
·
44
PDF
A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults
2022
·
Edgar Turner Overton
, Darja Schmidt
, et al.
·
Vaccine
·
21
PDF
A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study
2024
·
Elke Jordan
, Victoria Jenkins
, et al.
·
Vaccine
·
17
PDF
MVA-BN as monkeypox vaccine for healthy and immunocompromised
2020
·
E.T. Overton
, S. Lawrence
, et al.
·
International Journal of Infectious Diseases
·
13
Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial
2024
·
Carlos Fierro
, Heinz Weidenthaler
, et al.
·
Vaccine
·
12
Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine
2024
·
Richard N. Greenberg
, Darja Schmidt
, et al.
·
Human Vaccines & Immunotherapeutics
·
11
PDF
Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
2015
·
Richard N Greenberg
, Maria Yadira Hurley
, et al.
·
PLoS ONE
·
8
PDF
LB1579. A single and a two-dose regimen of MVA-BN elicit similar memory responses to a boost vaccination two years after the initial regimen, indicating potential flexibility for a delayed second dose of MVA-BN in the ongoing monkeypox emergency
2022
·
Heinz Weidenthaler
, Florian Lienert
, et al.
·
Open Forum Infectious Diseases
·
1
PDF
A Randomized Phase 3 Trial to Assess the Immunogenicity and Safety of 3 Consecutively Produced Lots of Freeze-Dried MVA‑BN® Vaccine in Healthy Adults
2022
·
Edgar Turner Overton
, Darja Schmidt
, et al.
·
SSRN Electronic Journal
·
1
Show more works
View as search
Works count:
29
Citation count:
2,693
H-index:
18
I10-index:
22
Year
Topic
Type